Reporting Guidelines: How CONSORT and EQUATOR Keep Trials Honest

Reporting guidelines are structured checklists that spell out what a published study must disclose so a reader can judge whether it was conducted and reported honestly. For randomized controlled trials, the dominant one is CONSORT, short for Consolidated Standards of Reporting Trials, now in its CONSORT 2025 edition: a 30-item checklist plus a participant flow diagram. CONSORT sits inside a larger library maintained by the EQUATOR Network, whose name captures the goal, Enhancing the QUAlity and Transparency Of health Research. A checklist cannot make a weak trial strong, but it can force the trial's design and results into the open, so you can see the weakness for yourself.

Reporting quality is not the same as trial quality

It helps to separate two ideas that are easy to blur. Methodological quality is whether a trial was well designed and well run. Reporting quality is whether the paper tells you enough to make that judgment. CONSORT governs the second. A trial can be rigorous and badly reported, or fragile and dressed up in confident language, and without complete reporting you cannot tell which you are reading. Repeated evaluations of the published literature have found that key details, from how patients were randomized to how missing data were handled, are frequently absent or vague. That gap is the problem reporting guidelines exist to close.

What CONSORT 2025 asks authors to disclose

The updated statement was published in April 2025, simultaneously in The BMJ, JAMA, The Lancet, Nature Medicine, and PLOS Medicine, and led by Sally Hopewell, An-Wen Chan, Isabelle Boutron, David Moher, Kenneth Schulz, and Gary Collins. It was not settled by opinion. The team ran a scoping review of the evidence, a Delphi survey of more than 300 participants, and a consensus meeting of international representatives before finalizing the wording. Compared with the long-standing 2010 version, CONSORT 2025 adds seven new items, revises three, deletes one, and folds in material from earlier extensions on harms, outcomes, and non-pharmacological treatments.

The most useful change for a reader is structural. A new open science section groups together trial registration, access to the protocol and statistical analysis plan, data sharing, and disclosure of funding and conflicts of interest. Other new items ask authors to describe patient and public involvement in the trial, how harms were defined and assessed, and how the intervention was actually delivered in practice. Each addition targets a place where selective or thin reporting has historically let weak evidence look stronger than it was. The aim is a public record that anyone can check afterward, including the clinicians and guideline panels who later rely on it to shape practice.

Reading a trial with the checklist in hand

You do not need to memorize 30 items to benefit from them. A few of the questions CONSORT forces onto the page do most of the work.

First, look for prospective registration and a linked protocol. If the primary outcome named in the registry matches the primary outcome in the paper, that is reassurance the result was not chosen after the data arrived. When they differ with no explanation, treat the headline finding cautiously, because outcome switching of this kind is one of the most common ways a modest trial gets reported as a success.

Second, read the flow diagram. It tracks how many people were randomized, how many received the assigned intervention, how many were lost to follow-up, and how many were analyzed. Large or lopsided dropout between groups can undo a positive result, and the diagram is where it becomes visible.

Third, check the open science items. Is the data sharing statement concrete, or boilerplate? Are funding and author conflicts disclosed? These do not prove bias, but their absence is itself information.

EQUATOR and the rest of the library

CONSORT is one guideline for one design. The EQUATOR Network, established in 2006, curates a searchable library of hundreds of reporting guidelines matched to different study types, and hosting CONSORT is part of that work. When you move from a randomized trial to another kind of study, the relevant checklist changes: PRISMA for systematic reviews and meta-analyses, STROBE for observational studies, STARD for diagnostic accuracy studies, and SPIRIT, the protocol-stage companion to CONSORT that was updated in parallel in 2025. Matching the guideline to the design is part of appraising the evidence, because a checklist written for a trial will not tell you whether an observational study accounted for confounding.

What a checklist cannot tell you

Complete reporting is a floor, not a verdict. A trial can satisfy every CONSORT item and still be small, underpowered, or built to answer a narrower question than its title suggests. The checklist guarantees you can see those limits, not that they are absent. Used well, CONSORT and the EQUATOR library shift the reader's question from whether a result sounds impressive to whether it can actually be checked, which is the more honest place to start. This article is for general education about evaluating evidence and is not medical advice.